Senti Biosciences Holdings Inc (SNTI)

In May 2026, Senti Biosciences filed a Schedule 13D/A indicating Celadon's backing and a Form 15 to deregister its Common Stock. In April 2026, the company announced a holding company reorganization. In March 2026, Senti Bio reported its Fourth Quarter and Full Year 2025 Financial Results, leading to a stock price change. In February 2026, the company's stock experienced a change. The company's share price has been volatile, with a minor risk due to weekly movements, and as of May 8, 2026, the stock price was $0.99.

As a clinical-stage biotechnology company with its lead product candidate in Phase 1 clinical trials and no approved commercial products, there is no information available regarding demand seasonality for Senti Biosciences Holdings, Inc.'s products or services.

Senti Biosciences Holdings, Inc. is a clinical-stage biotechnology company focused on developing cell and gene therapies using a synthetic biology platform that engineers "Gene Circuits" into medicines. Their product candidates include SENTI-202, a CAR-NK cell therapy for hematologic malignancies, SENTI-301A for hepatocellular carcinoma, and SENTI-401, another CAR-NK cell therapy.

Senti Biosciences, Inc.'s principal executive offices are located in South San Francisco, California, United States. The Phase 1 clinical trial for SENTI-202 is enrolling adult patients in both the United States and Australia.

Senti Biosciences has maintained a "Moderate Buy" consensus rating from analysts, with a consensus price target of $8.50. Positive impacts include the publication of preclinical data, announcement of positive data from the SENTI-202 Phase 1 trial, presentations at major conferences, and FDA Orphan Drug Designation for SENTI-202. Negative impacts include an auditor raising "Going Concern" doubt, high share price volatility, shareholder dilution, and the company's low revenue and unprofitability.

Senti Biosciences Holdings, Inc. has a significant level of institutional ownership, with 25.70% of its stock owned by institutional investors. As of May 4, 2026, there were 20 institutional owners and shareholders holding a total of 5,618,471 shares. Major institutional owners include Celadon Partners, NEA Management Company, LLC, and The Vanguard Group, Inc.